Company: HCTI
Filing Date: 2025-05-15
Form Type: 424B4
Source: 0001213900-25-044095
Chunk: 20

Company: Healthcare Triangle, Inc.
Filing Date: 2025-05-15
Form: 424B4
Chunk 20
---
 our Common Stock, investors should be aware that the occurrence of the events
described under the caption “Risk Factors” and elsewhere in this prospectus could have a material adverse effect on
our business, results of operations, and future financial performance.

Factors or events that could cause our actual
results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results,
levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States,
we do not intend to update any of the forward-looking statements to conform these statements to actual results.

<div align='center'>8

USE OF PROCEEDS</div>

This prospectus relates to the Common Stock
that may be offered and sold from time to time by the selling stockholders. We are not selling any shares of our Common Stock in this
offering, and we will not receive any of the proceeds from the sale of shares of our Common Stock by the selling stockholder. The selling
stockholders will receive all of the proceeds from any sales of the shares of our Common Stock offered hereby, however we will receive
the proceeds from any cash exercises of the Purchase Warrants; however as a result of the zero exercise price option we do not expect
to receive any cash proceeds from the exercise of the Series B Warrants.

<div align='center'>DIVIDEND POLICY</div>

We have never declared or paid any cash dividend
and do not anticipate paying any dividends in the foreseeable future. We currently intend to retain future earnings, if any, to finance
operations and expand our business. Our board of directors has sole discretion whether to pay dividends. If our board of directors decides
to pay dividends, the form, frequency and amount will depend upon our future operations and earnings, capital requirements and surplus,
general financial condition, contractual restrictions and other factors that our directors may deem relevant.

<div align='center'>9

THE PRIVATE PLACEMENT</div>

Background

On March 20, 2024 the Company received a notification
from Nasdaq that it did not comply with the minimum $2,500,000 stockholders’ equity requirement for continued listing set forth
in Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Rule”) and was given until September 16, 2024 to comply
with this requirement and such deadline was subsequently extended by the Panel. On February 20, 2025